Close Window
Aetna Aetna
Clinical Policy Bulletin:
Evacuation of Meibomian Glands
Number: 0797


Policy

Aetna considers devices for evacuating meibomian glands by means of heat and intermittent pressure for the treatment of meibomian gland dysfunction (e.g., the LipiFlow System) experimental and investigational because of insufficient evidence of their effectiveness.

Aetna considers tear film imaging (e.g., LipiView Ocular Surface Interferometer) experimental and investigational because its clinical value has not been established.



Background

Meibomian glands are large sebaceous glands that are located as separate gland strands in parallel arrangement within the tarsal plates of the eyelids.  Their oily product, meibum, is secreted via a holocrine mechanism during which meibocytes are transformed into the meibum.  Following production in the gland acini, meibum is transported through the ductal system via the connecting duct and the central duct towards the orifice at the free eyelid margin close to the inner eyelid border.  Meibum is a complex mixture of various lipids and minor protein components as well as other components of the meibocytes, which form a clear liquid at body temperature.  It is transported within the gland by the force of secretory pressure from continuous secretion and by muscular action of the orbicularis muscle and Riolans muscles during blinking.  After it is delivered onto the posterior eyelid margin, meibum moves from the posterior eyelid margin reservoir onto the tear meniscus and is pulled as a thin layer onto the pre-ocular tear film every time the eyelid opens.  During closure of the eyelid, it is compressed and a small part is continuously renewed.  Meibum also has a barrier function against the spillage of tears over the inner border of the eyelid and against the entry of skin lipids (sebum) from the free eyelid margin (Knop and Knop, 2009a; Knop et al, 2009).

Obstructive meibomian gland dysfunction (MGD) is a common source of complaint among patients with dry eye (DE) syndrome and its prevalence increases with age.  The principal clinical consequence of obstructive MGD is evaporative DE syndrome.  Moreover, chronic obstruction of the meibomian glands may also result in degeneration of the secretory gland tissue that can lead to a secondary hypo-secretion even if the primary obstruction is later resolved by therapeutic approaches.  Risk factors in the pathogenesis of obstructive MGD include age, hormonal disturbances and environmental influences (e.g., contact lenses).  Furthermore, qualitative alterations in the composition of the meibum may lead to hyper-keratinization of the ductal epithelium and increased viscosity of the meibum.  This can result in obstruction of the duct and orifice leading to a lack of meibum on the eyelid margin and tear film with downstream hyper-evaporative DE syndrome.  At the same time, obstruction leads to a stasis of meibum inside the meibomian gland with increased pressure and resulting dilatation of the ducts and in atrophy of the acini with rarefaction of the secretory meibocytes and gland dropout.  Stasis can also increase the growth of commensal bacteria, their production of oil degrading enzymes and release of toxic mediators.  These factors can act as self-enforcing feedback loops that aggravate the primary hyper-keratinization and compositional disturbance of meibum and can hence lead to a progressive MGD (Knop and Knop, 2009b).

Conventional treatments of obstructive MGD entail eyelid hygiene (e.g., lid washing and use of preservative-free artificial tears), omega-3 dietary supplementation (e.g., eicosapentaenoic acid and docosahexaenoic acid), topical antibiotics (e.g., bacitracin and erythromycin), topical corticosteroids, topical cyclosporine, oral antibiotics (e.g., doxycycline, minocycline, and tetracycline), oral omega-6 fatty acids (e.g., linoleic acid and gamma-linolenic acid), as well as unclogging of glands that are blocked, which can be achieved by applying warm compresses to the eyelid or gentle lid massaging (Olson et al, 2003; Romero et al, 2004; Yoo et al, 2005; Perry et al, 2006; Pinna et al, 2007; Souchier et al, 2008; and Foster et al, 2009).  Moreover, eyelid-warming devices have also been employed in the treatment of patients with MGD.  However, the effectiveness of these devices has not been established

In a prospective, non-comparative, interventional case series, Goto et al (2002) assessed the short term safety and effectiveness of an infra-red warm compression device as treatment for non-inflamed MGD.  In a total of 37 cases, subjective symptom scores and subjective face scores improved significantly, from 12.3 to 8.4, and from 7.0 to 5.3.  The results for tear evaporation rates during forced blinking, fluorescein staining, rose bengal staining, tear film break up time (BUT), and meibomian gland orifice obstruction score had also improved significantly at the end of the 2-week period of infra-red thermotherapy.  The authors concluded that the infra-red warm compression device was safe and effective for the treatment of MGD.  Moreover, they noted that while the results were promising, the small sample size and lack of comparison group limit the generalizability of the findings.

In a prospective, controlled, observer masked, single intervention trial, Mitra et al (2005) measured changes in tear film lipid layer thickness (LLT) and ocular comfort in normal subjects after 10 mins use of a novel device, which delivers meibomian therapy with latent heat.  A total of 24 normal subjects were randomized into three groups: Group I underwent 10 mins treatment with the activated device, Group II used the inactivated device for the same duration of time, and Group III had no intervention.  The LLT of each subject was measured with a Keeler Tearscope prior and subsequent to the 10-min period.  Subjective alteration in ocular comfort was also assessed.  Seven of 8 subjects (87.5 %) in Group I exhibited an increase in LLT.  The mean LLT in this group showed a statistically significant increase compared to Groups II and III.  Six of 8 subjects (75 %) using the activated device experienced subjective improvement in ocular comfort.

In a prospective, interventional clinical trial, Matsumoto et al (2006) evaluated the safety and effectiveness of an original warm moist air device on tear functions and ocular surface of patients with simple MGD.  A total of 15 patients with simple MGD and 20 healthy volunteers were enrolled in this study.  The device was applied to the eyes of the subjects for 10 mins.  Temperatures of the eyelids and corneas were measured with an infra-red thermometer.  Symptoms of ocular fatigue were scored using visual analog scales (VAS).  Schirmer test, tear film BUT, DR-1 tear film lipid layer interferometry, fluorescein staining, and rose bengal staining were also performed before and after the application of the eye steamer.  After the initial study, another 2-week, prospective, clinical trial was carried out in 10 patients with MGD who received the warm moist air treatment.  Ten other patients were also recruited and received warm compress treatment with hot towels for 2 weeks to evaluate the long-term effects of the warm moist air device and the warm compresses on tear film LLT and ocular surface health.  The warm moist air device and the warm compresses were applied for 10 mins twice-daily.  The changes in VAS scores for symptoms, tear film BUT values, fluorescein, and rose bengal staining scores were examined before and after each treatment during the second trial.  VAS scores of ocular fatigue improved significantly with short- and long-term applications of the warm moist air device in both studies.  The mean corneal surface and eyelid temperatures showed significant elevation within safe limits 10 mins after the moist air application.  The mean tear film BUT prolonged significantly in patients receiving warm moist air applications but did not change significantly in those treated with warm compresses.  DR-1 tear film lipid layer interference showed evidence of lipid expression in the patients and controls, with thickening of the tear film lipid layer after 10 mins of warm moist air device use.  In the 2-week trial, tear film LLT increased in both warm moist air device and warm compress groups, with a greater extent of increase in the warm moist air device group.  The authors concluded that the use of warm moist air device provided symptomatic relief of ocular fatigue and improvement of tear stability in patients with MGD.  The new warm moist air device appears to be a safe and promising alternative in the treatment of MGD.

Korb and Blackie (2011) determined (i) the pressure needed to express the first non-liquid material from non-functional lower lid meibomian glands, (ii) the pressure required to evacuate all of the expressible material from the glands (simulating the authors' methodology for therapeutic meibomian gland expression), and (iii) the level of pain associated with these procedures.  All patients (n = 28) were recruited from those presenting for ocular examinations at a single practice.  Custom instrumentation exerting pressures from 1.0 to 150.0 psi was developed to quantify the pressure applied during expression.  The instrument was applied to the inner surface of the lower lid.  The lid was then compressed between the thumb and the contact surface of the instrument.  The applied pressure was displayed on a digital meter.  The first procedure evaluated the pressure required to obtain the first non-liquid material from non-functional glands.  The second evaluated the pressure needed for evacuating all expressible gland contents.  The pain response was monitored throughout the procedure.  The pressure to obtain the first non-liquid material ranged from 5 to 40 psi (mean of 16.1 +/- 8.2 psi) and for the evacuation of expressible contents, from 10 to 40 psi (mean of 25.6 +/- 11.4 psi).  Only 7 % of the patients could tolerate the pressure necessary to administer complete therapeutic expression along the entire lower eyelid.  The authors concluded that forces of significant magnitude are needed for therapeutic expression.  Pain is the limiting factor for the conduct of this treatment.

In summary, there is currently insufficient evidence to support the use of devices for evacuating meibomian glands by means of heat and intermittent pressure for the treatment of MGD.

Tear Film Imaging (Ocular Surface Interferometry):

Interferometry is a non-invasive technique for recording tear film surface irregularities.  While this technique has been used to diagnose DE, it is hindered by natural eye movements resulting in measurement noise.  Currently, there is insufficient evidence to support the use of interferometry for the diagnosis of DE as a consequence of meibomian gland dysfunction or other cause such as hematopoietic stem cell transplantation (HSCT)

Savini et al (2008) noted that the currently available methods for the diagnosis of DE are still far from being perfect for a variety of reasons.  These researchers highlighted the advantages and disadvantages of both traditional tests (e.g., Schirmer's test, break-up time, and ocular surface staining) and innovative non-invasive procedures, including tear meniscus height measurement, corneal topography, functional visual acuity, tear interferometry, tear evaporimetry, as well as tear osmolarity assessment.

Ban and colleagues (2009) examined the changes in the tear film lipid layer in HSCT patients with DE associated with chronic graft-versus-host disease (cGVHD) and compared with HSCT recipients without DE.  These researchers performed a prospective study in 10 HSCT patients with DE associated with cGVHD and 11 HSCT recipients without DE.  They performed Schirmer's test, tear film break-up time examinations, ocular surface dye staining and meibum expressibility test and DR-1 tear film lipid layer interferometry.  DR-1 interferometry images of the tear film surface were assigned a “DR-1 grade” according to the Yokoi severity grading system.  The DR-1 grades were analyzed according to the presence or absence of DE, conjunctival fibrosis, as well as systemic cGVHD.  The mean DR-1 severity grade in patients with DE related to cGVHD (DE/cGVHD group; 3.9 +/- 0.9) was significantly higher than in patients without DE after HSCT (non-DE/non-cGVHD group; 1.3 +/- 0.6; p < 0.05).  The DR-1 grade for HSCT recipients with conjunctival fibrosis was significantly higher than in patients without conjunctival fibrosis (p < 0.05).  When DE severity was graded according to the recommendation of the 2007 Dry Eye Workshop Report, these findings showed a correlation between the severity of DE and DR-1 grades (r = 0.8812, p < 0.0001).  The authors concluded that DR-1 interferometry may be applicable to diagnosing DE and evaluating its progression subsequent to HSCT.

Blackie and colleagues (2009) examined the relationship between DE symptoms and LLT in patients presenting for routine eye examination.  Patients presenting consecutively for routine eye examinations were recruited (n = 137, age range of 18 to 60 years, mean of 41.7 +/- 15.5 years, 102 females and 35 males).  Patients were required to complete the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire after which their LLT was evaluated using a new interferometer (Ocular Surface Interferometer).  Patients were assigned to 1 of 3 symptom categories: (i) no symptoms (SPEED = 0), (ii) mild-to-moderate symptoms (SPEED = 1 to 9), and (iii) severe symptoms (SPEED greater than or equal to 10).  Categorical analysis (contingency table) and linear regression were performed on the data.  For patients with severe DE symptoms, 74 % had an LLT less than or equal to 60 nm.  Conversely, 72 % of patients with no DE symptoms had an LLT of greater than or equal to 75 nm (contingency table, Chi = 12.63, df = 2, p = 0.0018).  Furthermore, a linear regression of LLT and SPEED score reveal a significant linear relationship (as LLT increases, SPEED score decreases; p = 0.0014).  The authors concluded that these data indicated that approximately 3 of 4 patients reporting severe symptoms have relatively thin lipid layers of 60 nm or less, whereas approximately 3 of 4 patients without symptoms have relatively thick lipid layers of 75 nm or more.  Thus, the presence of DE symptoms significantly increases the likelihood of a relatively thin lipid layer.  Lipid layer thickness seems to correlate better to symptoms, especially severe symptoms, than other reported correlations with objective clinical tests for DE disease.  Moreover, they stated that interferometry has the potential to be a practical and useful addition to clinical practice.

Lane et al (2012) evaluated the safety and effectiveness of the LipiFlow System compared to the iHeat WC for adults with MGD.  This was a non-significant risk, prospective, open-label, randomized, cross-over, multi-center clinical trial.  A total of 139 subjects were randomized between LipiFlow (n = 69) and WC control (n = 70).  Subjects in the LipiFlow group received a 12-min LipiFlow treatment and were re-examined at 1 day, 2 weeks and 4 weeks.  Control subjects received a 5-min iHeat treatment with instructions to perform the same treatment daily for 2 weeks.  At 2 weeks, they crossed-over (LipiFlow Cross-over) and received the LipiFlow treatment.  Effectiveness parameters included MG assessment, tear break-up time (TBUT) and dry eye symptoms.  Safety parameters included adverse events, ocular health exam, ocular surface staining, intra-ocular pressure, visual acuity and discomfort.  LipiFlow resulted in significant improvement (p < 0.05) in MG secretion at 2 and 4 weeks (mean ± standard deviation at baseline = 6.3 ± 3.5; 2 weeks = 14.3 ± 8.7; 4 weeks = 16.7 ± 8.7); and TBUT at 2 and 4 weeks: (at baseline = 5.5 ± 2.9; 2 weeks = 6.9 ± 5.0; 4 weeks = 7.4 ± 5.5).  There was no significant change in MG secretion or TBUT in the control group.  LipiFlow resulted in a greater significant reduction in dry eye symptoms than the iHeat WC.  The cross-over group demonstrated similar significant improvement 2 weeks post-treatment with the LipiFlow.  There was no significant difference between groups in the incidence of non-serious, device-related adverse events.  The authors concluded that the LipiFlow System was significantly more effective than iHeat WC; they stated that these results supported its safety and effectiveness in the treatment of MGD and dry eye symptoms.  This was an industry-sponsored, open-label, single cross-over study with a relatively small sample size and short-term follow-up.  This study did not include a group receiving warm compresses only for 4 weeks.  It should be noted that although the control group did not show significant increases in MG and tear film metrics at 2 weeks, the control group did have a significant reduction in self-reported dry eye symptom frequency and severity.  Also, the control group was limited to 5 mins of warm compression therapy once-daily, while typical treatment for MGD consists of hot packs 3 to 4 times daily along with lid margin scrubs.  The findings of this study need to be validated by well-designed studies.

In a prospective, randomized, cross-over, observer-masked clinical trial, Finis and colleagues (2014a) compared the effectiveness of a single LipiFlow(®) treatment with combined lid warming and massage in patients with MGD.  Subjects were randomized to receive either a single 12-min LipiFlow-LipiFlow Thermal Pulsation (LTP) system treatment or to perform combined twice-daily lid warming and massage for 3 months.  All subjects were examined before, and 1 and 3 months after initiation of treatments.  Investigated parameters included subjective symptoms, lipid layer thickness, meibomian gland assessment, tear BUT, tear osmolarity, corneal and conjunctival staining, Schirmer test values, and tear meniscus height.  A total of 31 subjects completed the 3-month follow-up.  At 1 and 3 months, patients in the LipiFlow treatment group had a significant reduction in Ocular Surface Disease Index (OSDI) scores compared with those in the lid-margin hygiene group.  Both treatments produced a significant improvement in expressible meibomian glands compared to the baseline parameters, but no significant difference was noted between the 2 groups.  The other investigated objective parameters did not show a significant difference.  The authors concluded that results of this study showed that a single LipiFlow treatment is as least as effective as a 3-month, twice-daily lid margin hygiene regimen for MGD.  Moreover, they stated that the present study was observer-masked only, and therefore a placebo effect may have confounded any improvements in subjective symptoms and other parameters in both groups.

Finis and associates (2014b) stated that the quantitative measurement of the tear film lipid layer thickness is a relatively new and promising method.  However, so far it has not been investigated whether there is a diurnal or a day-to-day variability and whether certain factors are confounding the measurement of the lipid layer thickness.  In 3 different experimental settings, 10 subjects without known sicca syndrome were examined at 3 different time-points on one day, on 3 different days and before and after therapeutic expression of the Meibomian glands.  As a comparison, the parameters tear film BUT, tear meniscus height, diagnostic expression of the Meibomian glands and subjective symptoms, determined using the OSDI questionnaire, were measured.  The results of the study showed a smaller variation of the lipid layer thickness measurements during the day and from day to day compared to the tear film BUT.  The expression of the Meibomian glands significantly increased the lipid layer thickness.  There was a correlation between the baseline values of tear film BUT and the lipid layer thickness.  The authors concluded that these findings data showed that the lipid layer thickness as measured with the Lipiview® interferometer appears to be a relatively constant parameter over time.  In addition, the expression of the Meibomian glands could be identified as a potential confounding factor.  In this study these investigators included only healthy subjects without known sicca syndrome; these findings need to be validated in dry eye patients.

 
CPT Codes / HCPCS Codes / ICD-9 Codes
CPT codes not covered for indications listed in the CPB:
0207T Evacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral
0330T Tear film imaging, unilateral or bilateral, with interpretation and report
ICD-9 codes not covered for indications listed in the CPB (not all-inclusive):
373.00 Blepharitis, unspecified (posterior blepharitis)
373.11 Hordeolum externum [meibomian stye]
373.12 Hordeolum internum [infected meibomian cyst]
373.2 Chalazion [meibomian cyst]
373.8 Other inflammations of eyelids
373.9 Unspecified inflammation of eyelid
374.85 Vascular anomalies of eyelid [meibomian infarct]
375.11 Dacryops
375.15 Tear film insufficiency, unspecified (dry eye syndrome)
375.20 Epiphora, unspecified as to cause
375.21 Epiphora due to excess lacrimation
375.22 Epiphora due to insufficient drainage
375.9 Unspecified disorder of lacrimal system


The above policy is based on the following references:
  1. Goto E, Monden Y, Takano Y, etal. Treatment of non-inflamed obstructive meibomian gland dysfunction by an infrared warm compression device. Br J Ophthalmol. 2002;86(12):1403-1407.
  2. Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens. 2003;29(2):96-99.
  3. Romero JM, Biser SA, Perry HD, et al. Conservative treatment of meibomian gland dysfunction. Eye Contact Lens. 2004;30(1):14-19.
  4. Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol. 2005;19(4):258-263.
  5. Mitra M, Menon GJ, Casini A, et al. Tear film lipid layer thickness and ocular comfort after meibomian therapy via latent heat with a novel device in normal subjects. Eye. 2005;19(6):657-660.
  6. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006;25(2):171-175.
  7. Matsumoto Y, Dogru M, Goto E, et al. Efficacy of a new warm moist air device on tear functions of patients with simple meibomian gland dysfunction. Cornea. 2006;25(6):644-650.
  8. Pinna A, Piccinini P, Carta F. Effect of oral linoleic and gamma-linolenic acid on meibomian gland dysfunction. Cornea. 2007;26(3):260-264.
  9. Souchier M, Joffre C, Grégoire S, et al. Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment. Br J Ophthalmol. 2008;92(6):819-822.
  10. Knop N, Knop E. Meibomian glands. Part I: Anatomy, embryology and histology of the Meibomian glands. Ophthalmologe. 2009a;106(10):872-883.
  11. Knop E, Knop N, Schirra F. Meibomian glands. Part II: Physiology, characteristics, distribution and function of meibomian oil. Ophthalmologe. 2009;106(10):884-892.
  12. Knop E, Knop N. Meibomian glands: Part IV. Functional interactions in the pathogenesis of meibomian gland dysfunction (MGD). Ophthalmologe. 2009b;106(11):980-987.
  13. Foster CS, Yuksel C, Anzaar F, Ekong AS. Dry eye syndrome: Treatment & medication. emedicine, May 13, 2009. Available at: http://emedicine.medscape.com/article/1210417-treatment. Accessed January 11, 2010.
  14. Korb DR, Blackie CA. Meibomian gland therapeutic expression: Quantifying the applied pressure and the limitation of resulting pain. Eye Contact Lens. 2011;37(5):298-301.
  15. Savini G, Prabhawasat P, Kojima T, et al. The challenge of dry eye diagnosis. Clin Ophthalmol. 2008;2(1):31-55.
  16. Ban Y, Ogawa Y, Goto E, et al. Tear function and lipid layer alterations in dry eye patients with chronic graft-vs-host disease. Eye (Lond). 2009;23(1):202-208.
  17. Blackie CA, Solomon JD, Scaffidi RC, et al. The relationship between dry eye symptoms and lipid layer thickness. Cornea. 2009;28(7):789-794.
  18. Lane SS, DuBiner HB, Epstein RJ, et al. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea. 2012;31(4):396-404.
  19. Finis D, Hayajneh J, Konig C, et al. Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: A prospective, randomized, observer-masked trial. Ocul Surf. 2014a;12(2):146-154.
  20. Finis D, Pischel N, Borrelli M, et al. Factors influencing the measurement of tear film lipid layer thickness with interferometry. Klin Monbl Augenheilkd. 2014b;231(6):603-610.


email this page   


Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
Aetna
Back to top